L-798106
SIGMA/L4545 - ≥98% (HPLC)
Synonym: (2E)
CAS Number: 244101-02-8
Empirical Formula (Hill Notation): C27H22BrNO4S
Molecular Weight: 536.44
MDL Number: MFCD08272644
Linear Formula: C27H22BrNO4S
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | powder |
| InChI | 1S/C27H22BrNO4S/c1-33-25- |
| InChI key | ODTKFNUPVBULRJ-NTCAYCPXSA |
| originator | Merck & Co., Inc., Kenilworth, NJ, U.S. |
| Quality Level | 100  |
| SMILES string | COc1ccc(Br)cc1S(=O)(=O)NC |
| solubility | DMSO: >20 mg/mL |
| storage temp. | 2-8°C |
| Application: | L-798106, a selective prostanoid receptor EP3 antagonist, is used in prostanoid receptor signaling studies that regulate COX-2 levels and the central excitatory effects of PGE(2) on PVN neurons. |
| Biochem/physiol Actions: | L-798106 is a potent, selective prostanoid receptor EP3-selective antagonists. |
| Biochem/physiol Actions: | L-798106 was among the first prostanoid receptor EP3-selective antagonists. It has been used in multiple studies to tease out EP3 agonist activity, both in vitro and in vivo. It successfully blocks the actions of sulprostone, an EP3-selective agonist, and it helped show that the vascular contraction effect of PGE2 is due to its prostanoid EP3 agonist activity. |
| Features and Benefits: | This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Hazard statements | H413 |
| Precautionary statements | P273 - P501 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352204 |